UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant \boxtimes

Filed by a Party other than the Registrant \Box

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material under §240.14a-12

Verve Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- \boxtimes No fee required.
- □ Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



Verve Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 15, 2023


For Stockholders of record as of April 20, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy statement, annual report, directions to register for the annual meeting and voting instructions, go to: www.proxydocs.com/VERV

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



Verve Therapeutics, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ON EACH OF THE NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2.

PROPOSAL

- 1. Election of three Class II directors to our board of directors, each to serve until the 2026 annual meeting of stockholders;
 - 1.01 Alexander Cumbo
 - 1.02 Michael MacLean
 - 1.03 Sheila Mikhail, J.D.
- Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 2. 31, 2023.

Note: To consider and act upon other such business as may properly come before the meeting or any adjournment thereof.